Applied BioCode Corporation (6598.TW)
Taiwan · TWD · Healthcare · Medical Devices
NT$29.60 (-2.31%) as of
Key statistics
- Market cap
- 3.04B
- Forward P/E
- -18.50
- EPS (TTM)
- -0.48
- Dividend yield
- 0.00%
- 52-week range
- 20.50 – 31.90
- Beta
- 0.62
- Revenue (TTM)
- 666.54M
- Profit margin
- -7.33%
- Volume
- 226.09k
About Applied BioCode Corporation
Applied BioCode Corporation designs, develops, and commercializes multiplex diagnostic testing products in California. Its products include the BioCode MDx 3000 system, an automated molecular diagnostic system that automates the detection steps, PCR amplification, and hybridization and target capture; and the BioCode 2500 analyzer, a system that reads each barcode and quantifies the BMB target using the fluorescence signal intensity. The company develops assays, such as BioCode SARS-CoV-2 Assay, an assay for the detection of SARS-CoV-2 nucleic acid in nasopharyngeal swabs; and CoV-2 Flu Assay for detection of RNA and various Influenza, as well as offers gastrointestinal and respiratory pathogen panel related products. In addition, it provides BioCode Fungal Panel, a multiplexed deoxyribonucleic acid (DNA) amplification test; and BioCode STI + Resistance Panel (RUO), a multiplex nucleic acid amplification test. Further, the company offers barcoded magnetic bead accessories. Applied BioCode Corporation was founded in 2016 and is based in Grand Cayman, the Cayman Islands.
- Sector
- Healthcare
- Industry
- Medical Devices
- Headquarters
- Grand Cayman, Cayman Islands
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.